down arrow

Nurix Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US67080M1036
USD
18.02
1.67 (10.21%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
SIGA Technologies, Inc.
Zymeworks, Inc.
Liquidia Corp.
Marinus Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc.
Nurix Therapeutics, Inc.
Procaps Group SA
Oculis Holding AG
Icosavax, Inc.
Cullinan Therapeutics, Inc.
Biomea Fusion, Inc.
Why is Nurix Therapeutics, Inc. ?
1
Negative results in May 25
  • OPERATING CASH FLOW(Y) Lowest at USD -215.18 MM
  • NET PROFIT(9M) At USD -158.36 MM has Grown at -23.7%
  • DEBT-EQUITY RATIO (HY) Highest at -96.93 %
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -22.09%, its profits have fallen by -44%
3
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -22.09% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Nurix Therapeutics, Inc. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Nurix Therapeutics, Inc.
-13.74%
0.17
66.30%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
35.30%
EBIT Growth (5y)
-228.42%
EBIT to Interest (avg)
-164.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.22
Tax Ratio
0.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.03
EV to EBIT
-1.87
EV to EBITDA
-2.02
EV to Capital Employed
-6.94
EV to Sales
7.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-43.33%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company
ROCE(HY)

Highest at -50.67%

NET SALES(Q)

Highest at USD 44.06 MM

RAW MATERIAL COST(Y)

Fallen by -34.16% (YoY

CASH AND EQV(HY)

Highest at USD 1,035.46 MM

OPERATING PROFIT(Q)

Highest at USD -43.23 MM

OPERATING PROFIT MARGIN(Q)

Highest at -98.11 %

PRE-TAX PROFIT(Q)

Highest at USD -42.7 MM

NET PROFIT(Q)

Highest at USD -43.46 MM

EPS(Q)

Highest at USD -0.52

-6What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -215.18 MM

NET PROFIT(9M)

At USD -158.36 MM has Grown at -23.7%

DEBT-EQUITY RATIO (HY)

Highest at -96.93 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 8.3 times

Here's what is working for Nurix Therapeutics, Inc.
Net Sales
At USD 44.06 MM has Grown at 212.36%
over average net sales of the previous four periods of USD 14.1 MM
MOJO Watch
Near term sales trend is extremely positive

Net Sales (USD MM)

Net Sales
Highest at USD 44.06 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Operating Profit
Highest at USD -43.23 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at -98.11 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at USD -42.7 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -43.46 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0.52
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv
Highest at USD 1,035.46 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by -34.16% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 5.1 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Nurix Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -215.18 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debt-Equity Ratio
Highest at -96.93 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 8.3 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."